Effects of an Intensive Rhythmic Dance Program on Learning Skills in Children With Cerebral Palsy (DANS-SCED)

March 24, 2026 updated by: University Hospital, Toulouse

Effects of an Intensive Rhythmic Dance Program on Learning Ability in Children With Cerebral Palsy

Cerebral palsy is a neurological disorder that affects 1 in 1,000 children and causes motor disability , with sometimes sensorymotor disability which have consequences on daily life. The aim of rehabilitation for people with cerebral palsy is to improve patients' independence and quality of life. A major stake for these people is therefore to learn new behaviors by fostering motor, cognitive, and psychosocial development. Dance is a relevant activity, as it is a physical and enjoyable learning activity and a multisensory environment. Moreover, scientific literature suggests motor and psycho-affective benefits associated with dance practice in children with cerebral palsy, especially when it involves rhythmic stimulation. The aim of this project is therefore to assess the effect of a rhythm-based dance program on motor learning ability, as rhythmic auditory stimulation can improve motor control in patients with other neurological disorders (e.g., Thaut, 2015). We suppose that being able to synchronize through the practice of rhythmic dance could facilitate the learning of cognitive and psychosocial motor skills.

To reach this goal, we will conduct a Single Case Experimental Study (SCED). Using this individual analysis method, we will repeatedly evaluate a target behavior to determine whether a dance program facilitates motor, cognitive, and psychosocial learning for each participant.

The dance program will take place over two weeks. Three instructors will lead dance classes (two 2-hour sessions per day with breaks) during the first week, and three one-hour dance classes during the second week. Assessments will be conducted before (baseline, phase A), during (intervention, phase B), after the dance workshop (follow-up phase, FU), and far from it (final study visit).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
6

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
    • Occitanie
      • Toulouse, Occitanie, France, 31059
        • Recruiting
        • CHU Toulouse - Hôpital Raymonde Fournet
        • Contact:
        • Principal Investigator:
          • Philippe MARQUE

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Participants with cerebral palsy will be recruited from ASEI ((Agir, Soigner, Eduquer, Insérer), a public utility organization governed by the French law of July 1, 1901).

Description

Inclusion Criteria:

  • Age between 6 and 17 years old
  • Diagnosis of cerebral palsy
  • Level I to IV on the Gross Motor Function Classification System (GMFCS, Palisano et al., 2008) : with or without an armchair
  • Level I to IV on the Manual Ability Classification System (MACS, Eliasson et al., 2006)
  • Affiliation with or beneficiary of a Social Security scheme
  • Ability to understand instructions (investigator's assessment)

Exclusion Criteria:

  • Autism spectrum disorder diagnosed according to DSM-5 criteria (APA, 2013)
  • Hearing impairment diagnosed according to DSM-5 criteria (APA, 2013) or uncorrected hearing impairment that prevents the individual from hearing music at a volume between 45 and 70 decibels
  • Visual impairment diagnosed according to DSM-5 criteria (APA, 2013) and uncorrected
  • Intellectual Developmental Disorder diagnosed according to DSM-5 criteria (APA, 2013)
  • Behavioral/conduct disorders diagnosed according to DSM-5 criteria (APA, 2013)
  • Child enrolled in a dance program specifically focused on rhythm
  • Child whose parents are both subject to legal protection measures (guardianship, curatorship, judicial protection)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Evolution of the Goal Attainment Scaling (GAS) score throughout the study
Time Frame: From baseline to the final study visit (up to approximately 9 weeks)
The main criterion is the evolution of the Goal Attainment Scaling (GAS) score throughout the study. The GAS corresponds to the individual goals set with each child at the beginning of the study. Three individualized and specific goals will be defined for each child, covering motor, cognitive, and psychosocial domains. These measurements will be assessed repeatedly during the dance program: reference phase (baseline, phase A), during the dance program (intervention, phase B), and after the dance program (follow-up phase, FU), with a final assessment at a distance from the intervention phase (final study visit).
From baseline to the final study visit (up to approximately 9 weeks)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Intrinsic Motivation Inventory (IMI) scores
Time Frame: From baseline to the final study visit (up to approximately 9 weeks)
Children's perceptions will be assessed using the Intrinsic Motivation Inventory adapted for children with cerebral palsy ). This questionnaire evaluates interest and enjoyment in performing an activity, skills involved perception, perceived value and activity usefulness, the feeling of freedom and choice, and perceived pressures and tensions. These measurements will be assessed repeatedly during the dance program: reference phase (baseline, phase A), during the dance program (intervention, phase B), and after the dance program (follow-up phase, FU), with a final assessment at a distance from the intervention phase (final study visit).
From baseline to the final study visit (up to approximately 9 weeks)
Physical activity levels measured by heart rate monitoring
Time Frame: From baseline to the final study visit (up to approximately 9 weeks)
Physical activity levels will be measured using a heart rate monitor. These measurements will be assessed repeatedly during phase A, during the dance program (phase B), and after the dance program (follow-up phase, FU). A final assessment will be conducted remotely after the intervention phase (final study visit).
From baseline to the final study visit (up to approximately 9 weeks)
Socio-demographic characteristics
Time Frame: baseline
Socio-demographic characteristics is a composite measure derived age, sex, practice habits (Physical Activity (PA), dance, PA related to rhythm) will be collected via an interview grid at the beginning of the study.
baseline
Initial perceptions of the children
Time Frame: baseline
The initial perceptions of the children and their parents regarding their self-image in relation to dance (perceived ability and expected progress) and the effects of the dance program will be collected at the beginning of the study using a semi-structured interview, and the evolution of these perceptions will be analyzed qualitatively
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Toulouse

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 17, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 24, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 24, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 30, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 30, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 24, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RC31/25/0654

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Palsy (CP)

Clinical Trials on Repeated assessments

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings